Cholangiocarcinoma (Bile Duct Cancer) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Cholangiocarcinoma (Bile Duct Cancer) Market Outlook

Thelansis's "Cholangiocarcinoma (Bile Duct Cancer) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cholangiocarcinoma (Bile Duct Cancer) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cholangiocarcinoma (Bile Duct Cancer) Overview

Cholangiocarcinoma is a malignancy arising from biliary epithelial cells, classified as intrahepatic, perihilar, or distal, driven by chronic biliary inflammation, FGFR2 fusions, IDH1/2 mutations, and KRAS alterations promoting oncogenic transformation. It presents with progressive obstructive jaundice, pruritus, weight loss, and abdominal pain, with perihilar tumors causing early biliary obstruction. Diagnosis integrates MRI/MRCP, CA19-9, and tissue biopsy with molecular profiling; vascular involvement and metastatic spread define resectability. Surgical resection remains the only curative option; gemcitabine-cisplatin with durvalumab is the standard first-line systemic regimen. FGFR2 and IDH1 inhibitors provide targeted options in molecularly selected patients. Biliary drainage optimizes symptom control. Early palliative integration and goals-of-care planning are essential given poor overall prognosis.

Key Highlights

• In Germany, diagnosed cholangiocarcinoma cases are projected to increase from approximately 4,388 in 2025 to 4,612 by 2035.
• CCA remains an aggressive biliary tract malignancy associated with poor prognosis and limited survival.
• Late-stage diagnosis continues to contribute to significant disease burden and mortality.
• Molecular profiling is increasingly enabling targeted treatment approaches.
• FGFR inhibitors, IDH inhibitors, and immunotherapies are expanding therapeutic options.

Market Overview

• The Germany cholangiocarcinoma market is projected to grow from approximately $200 MN to $680 MN by 2035.
• Market growth is supported by:
• Increasing adoption of targeted therapies and immunotherapy
• Growing use of biomarker-driven treatment strategies
• Market value growth is driven by premium oncology therapies and expanding eligible patient populations.
• Future growth will depend on precision oncology advancements and next-generation targeted treatments.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genfit
• RedHill Biopharma Limited
• Eisai Co., Ltd.
• Incyte Corporation
• Servier
• Virogin Biotech Ltd.
• 3D Medicines (Beijing) Co., Ltd.
• TransThera Sciences (Nanjing), Inc.
• Taiho Oncology, Inc.
• Boehringer Ingelheim
• Verismo Therapeutics
• Hutchmed
• Medivir
• Eli Lilly and Company
• Bold Therapeutics, Inc.
• Elevar Therapeutics
• Rigel Pharmaceuticals
• Compass Therapeutics
• Toray Industries, Inc.
• MacroGenics
• Cogent Biosciences, Inc.
• Pheast Therapeutics
• Leap Therapeutics, Inc.
• Seagen, a wholly owned subsidiary of Pfizer
• SOFIE
• TCR2 Therapeutics
• Alentis Therapeutics AG
• Elicio Therapeutics
• Arbele Pty Ltd.
• Apollo Therapeutics Ltd.
• Context Therapeutics Inc.
• Merck Sharp & Dohme LLC
• Celldex Therapeutics
• Hoffmann-La Roche